GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Enterprise Value

ImmuCell (ImmuCell) Enterprise Value : $53.77 Mil (As of May. 01, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ImmuCell's Enterprise Value is $53.77 Mil. ImmuCell's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.29 Mil. Therefore, ImmuCell's EV-to-EBIT ratio for today is -10.16.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, ImmuCell's Enterprise Value is $53.77 Mil. ImmuCell's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.58 Mil. Therefore, ImmuCell's EV-to-EBITDA ratio for today is -20.87.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, ImmuCell's Enterprise Value is $53.77 Mil. ImmuCell's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $17.47 Mil. Therefore, ImmuCell's EV-to-Revenue ratio for today is 3.08.


ImmuCell Enterprise Value Historical Data

The historical data trend for ImmuCell's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Enterprise Value Chart

ImmuCell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.79 45.74 62.02 53.94 55.16

ImmuCell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.94 50.06 52.38 56.06 55.16

Competitive Comparison of ImmuCell's Enterprise Value

For the Biotechnology subindustry, ImmuCell's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuCell's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Enterprise Value distribution charts can be found below:

* The bar in red indicates where ImmuCell's Enterprise Value falls into.



ImmuCell Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

ImmuCell's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

ImmuCell's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmuCell  (NAS:ICCC) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

ImmuCell's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=53.769/-5.294
=-10.16

ImmuCell's current Enterprise Value is $53.77 Mil.
ImmuCell's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.29 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

ImmuCell's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=53.769/-2.576
=-20.87

ImmuCell's current Enterprise Value is $53.77 Mil.
ImmuCell's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.58 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

ImmuCell's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=53.769/17.473
=3.08

ImmuCell's current Enterprise Value is $53.77 Mil.
ImmuCell's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmuCell Enterprise Value Related Terms

Thank you for viewing the detailed overview of ImmuCell's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuCell (ImmuCell) Business Description

Traded in Other Exchanges
Address
56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.
Executives
Bryan K. Gathagan director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen director C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin other: See Explanation of Responses C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin other: See Explanation of Responses 310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb director, officer: Vice President and CSO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams officer: Vice Pres. of Mfg Operations C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild director, 10 percent owner C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham director, officer: President and CEO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde other: Director of Sales and Marketin 56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce director 56 EVERGREEN DRIVE, PORTLAND ME 04103